Glafabra Therapeutics key facts
- Provider of living cellular therapy services intended to treat enzyme deficiency disorders through a repeat-infusion model.
- Glafabra Therapeutics’s last known valuation is $65.0M.
- It has raised $200K.
- Notable investors include Innosphere Ventures, Rogue Funds.
- Status: Privately Held (backing).
Who backs Glafabra Therapeutics
2- ·Watch Glafabra Therapeutics: the Monday email on marks, rounds and moves
Glafabra Therapeutics funding rounds
No funding rounds for Glafabra Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Glafabra Therapeutics valuation
Glafabra Therapeutics's last known valuation is $65 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
Glafabra Therapeutics investors
2 investors are on record for Glafabra Therapeutics, including Innosphere Ventures and Rogue Funds.
About Glafabra Therapeutics
Provider of living cellular therapy services intended to treat enzyme deficiency disorders through a repeat-infusion model. The company uses engineered hematopoietic stem cells to restore missing enzymes, enabling patients with enzyme deficiencies to achieve durable therapeutic outcomes and reduced treatment frequency.
- Sector
- Healthcare
- HQ
- Park City, UT, United States
- Founded
- 2025
- Employees
- 12
- Website
- glafabra.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Glafabra Therapeutics’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.